Davita Inc vs iShares 7-10 Year Treasury Bond ETF — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while iShares 7-10 Year Treasury Bond ETF trades at $89.42 (market cap $41.13B). The key difference: iShares 7-10 Year Treasury Bond ETF is far larger — about 3.6× Davita Inc's market cap, and Davita Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and iShares 7-10 Year Treasury Bond ETF for 108 Days on average.
| DVA | IEF | |
|---|---|---|
Market Cap | $11.29B | $41.13B |
Volume | 582,204 | 10,340,382 |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $97.99 |
52-Week Low | $103.87 | $88.92 |
Typical Hold Time | 114 Days | 108 Days |
Enterprise Value | $24.01B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.25, up 1.4% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish moving averages but neutral oscillators, trading near resistance at $179. Fundamentally, revenue growth continues with 2025 revenue reaching $13.64B, though net margins compressed to 5.47% from 7.3% in 2024. Recent partnership expansion with Humana for value-based kidney care represents significant growth opportunity.
Outlook remains positive with analyst consensus target of $235.67 implying 31% upside, though elevated debt levels and regulatory risks require monitoring. The company benefits from demographic tailwinds in kidney care services and strong institutional support, including Berkshire Hathaway's 45% stake, providing stability amid market volatility.
IEF is trading at $89.40, up 0.33% with a bearish technical signal. The ETF shows neutral oscillators but bearish moving averages, with key support at $89 and resistance at $90. Recent dividend payments of $0.31-$0.33 per share provide income, while financial ratios remain unavailable. Market sentiment reflects defensive positioning amid Treasury yield volatility.
Outlook remains cautious due to technical bearishness and bond market pressures. Opportunities include income from dividends and potential stability in defensive portfolios. Risks include continued bond market volatility and macroeconomic uncertainty affecting Treasury yields.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →